Rexahn Pharmaceuticals, Inc. (RNN) Reports Solid Phase IIa Results for Anti-Depressant Drug
Risk is just that, risk. Investing in opportunity is never easy but can return financial rewards. Understanding the risk is the key. Pick an investment that fits your needs. Finding that investment, and waiting to see if you are correct, is the key. Rexahn Pharmaceuticals Inc., a clinical biopharmaceutical drug development company, works to develop drug products oriented toward a variety of conditions. The company is currently progressing through Phase IIa for an anti-depressant product. Although the company has a variety of pharmaceutical products in development, its relationships around the world may be its largest asset. Universities to corporations have…